Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Price Target at $21.00

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has earned an average recommendation of “Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $21.00.

Separately, HC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 price target on the stock.

Institutional Trading of Artiva Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth $42,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Artiva Biotherapeutics during the fourth quarter worth $52,000. Wells Fargo & Company MN increased its position in shares of Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares during the period. MetLife Investment Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth $135,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth $166,000.

Artiva Biotherapeutics Stock Down 12.3 %

ARTV stock opened at $4.44 on Friday. The firm’s 50 day moving average price is $5.27 and its 200-day moving average price is $9.59. Artiva Biotherapeutics has a one year low of $3.37 and a one year high of $17.31.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.